Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>Resources>Application Notes>This Application Note
  Application Notes
Scientific News
Flu Vaccine May Reduce Risk of Death For Type 2 Diabetes Patients
Researchers at Imperial College London have suggested that the vaccine may have substantial benefits for patients with long-term conditions.
Flu Vaccine May Reduce Death Risk of Type 2 Diabetes
New research suggests that a new flu vaccine may reduce probability of type 2 diabetes patients being hospitalised with stroke and heart failure.
Disrupting Tumour-Promotion in Humans
Researchers have modified an existing protein to represses a specific cancer-promoting ‘message’ within cells.
Protein Nanocages Could Improve Drug Design and Delivery
HHMI scientists have designed and built 10 large protein icosahedra that are similar to viral capsids that carry viral DNA.
Vaccine Strategy Targets Multiple Influenza Viruses
Scientists have identified vaccine-induced antibodies that can neutralize strains of influenza virus that infect humans.
Antibody-Based Drug for Multiple Sclerosis
New antibody-based drug paves the way for new strategies for controlling and treating multiple sclerosis.
Structure of Cold Virus Solved
Researchers have identified the structure of an elusive cold virus linked to child asthma and respiratory infections, providing the foundation for treating the virus.
'Poison Pill' Fed to Deadly Virus
Researchers have created a genetic modification within a virus (with funny name), rendering it unable to replicate, mutate or cause illness.
World First Alzheimer's Vaccine Breakthrough
Researchers have made a breakthrough discovery towards an effective vaccine for Alzheimer's by targeting associated proteins.
Immunotherapy Drug Combo Targets Cancer
Mayo Clinic researchers identify potential immunotherapy drug combination that shows therapeutic effects against advanced and metastatic cancers.
Scroll Up
Scroll Down

Performing ADCC Reporter Bioassay with an Environmentally Controlled Microplate Reader
Bookmark and Share

Tecan Group Ltd.

Bioassays designed to measure antibody-dependent cell-mediated cytotoxicity (ADCC) are particularly useful when looking to understand and characterize mechanism of action, and to quantify biologic potency and stability of target compounds during discovery and development.

However, the labor and skill required to isolate primary natural killer cells for ADCC or to maintain alternative cell lines in culture with any level of reproducibility remains problematic, with high costs in consumable reagents and in purchasing and maintaining basic equipment.

Promega has developed reporter bioassays that use activation of gene transcription through NFAT (nuclear factor of activated T-cells) as an earlier measure of ADCC. The bioassays use frozen, thaw-and-use effector and target cells and eliminates the need for cell culture maintenance. The use of frozen cells also decreases assay variability. 

The ADCC Reporter Bioassay requires six-hour incubation with cells and antibody for optimal NFAT activation and luciferase expression to occur.The Tecan Infinite® 200 PRO, equipped with an external module that enables simultaneous adjustment of CO2 and O2, provides an alternative method enabling scientists without access to a cell culture facility to easily perform the bioluminescent reporter bioassay.

Further Information


Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,900+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!